Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
Avacta Life Sciences Ltd
Boehringer Ingelheim
Pfizer
Seagen Inc.
AstraZeneca
National Institutes of Health Clinical Center (CC)
Kivu Bioscience Inc.
University Health Network, Toronto
BeOne Medicines
University of Chicago
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Eli Lilly and Company
Debiopharm International SA
Novartis
University of Maryland, Baltimore
Boehringer Ingelheim
NiKang Therapeutics, Inc.
MacroGenics
Amgen
SystImmune Inc.
SN BioScience
Boundless Bio, Inc.
Centre Antoine Lacassagne
H. Lee Moffitt Cancer Center and Research Institute
Boehringer Ingelheim
SciTech Development, Inc.
AbbVie
Amgen
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Amgen
National Cancer Institute (NCI)
Nerviano Medical Sciences
Boehringer Ingelheim
AbbVie
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Janux Therapeutics
Novartis
National Cancer Institute (NCI)
Amgen
Sichuan Baili Pharmaceutical Co., Ltd.
NiKang Therapeutics, Inc.
Novelty Nobility, Inc.
Hangzhou DAC Biotechnology Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Bristol-Myers Squibb